Cargando…

Reduction in the weight, gained due to dolutegravir, following switch to bictegravir

BACKGROUND: HIV-infected individuals can live with the virus for decades, and the physicians have to review the long-term health implications of weight gain as they would for any other patient. Although the integrase strand transfer inhibitors (INSTIs) class of drugs are one of the most popular regi...

Descripción completa

Detalles Bibliográficos
Autores principales: Saple, Dattatray, Save, Sushrut, Powar, Ishita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282705/
https://www.ncbi.nlm.nih.gov/pubmed/35846543
http://dx.doi.org/10.4103/ijstd.ijstd_73_21
_version_ 1784747163846180864
author Saple, Dattatray
Save, Sushrut
Powar, Ishita
author_facet Saple, Dattatray
Save, Sushrut
Powar, Ishita
author_sort Saple, Dattatray
collection PubMed
description BACKGROUND: HIV-infected individuals can live with the virus for decades, and the physicians have to review the long-term health implications of weight gain as they would for any other patient. Although the integrase strand transfer inhibitors (INSTIs) class of drugs are one of the most popular regimens used for rapid reduction and maintenance in HIV cases, the weight gain resulting from their use is concerning. The use of dolutegravir (DTG) an INSTI is observed to have a weight gain in people living with HIV. Since bictegravir is also an INSTI, it is expected to show a similar weight gain. OBJECTIVE: This retrospective analyses the change in the weight in 22 patients, who showed a trend of increase in weight when on DTG and later when switched to bictegravir therapy showed reduction in the increased weight. METHODS: This is a retrospective analysis from our clinic (Dr. Saple's Clinic) in Mumbai from the duration of March 2018 to March 2021. Excessive weight gain was observed when the patients were on DTG therapy. The therapy was then switched to an equally potent integrase strand inhibitor bictegravir to get the benefit of efficacy of antiretroviral therapy and avoid the weight gain effect seen with DTG. RESULTS: In our case review, we found results contrary to this. After 22 patients were treated on DTG for 9 to 24 months (mean 20.68 months), the baseline weight of 74.04 kg increased significantly to 84.26 kg (P < 0.05). After switching over to bictegravir for a mean period of 8 – 12 months (mean 11.72 months), this weight reduced to mean of 77.08 kg, a drop was clinically observed but was not statistically significant. CONCLUSION: Our finding could be the first instance were weight loss has been reported post switching the patients from DTG therapy to Bictegravir. Considering smaller patient population this outcome may need further confirmed through large group study.
format Online
Article
Text
id pubmed-9282705
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-92827052022-07-15 Reduction in the weight, gained due to dolutegravir, following switch to bictegravir Saple, Dattatray Save, Sushrut Powar, Ishita Indian J Sex Transm Dis AIDS Original Article BACKGROUND: HIV-infected individuals can live with the virus for decades, and the physicians have to review the long-term health implications of weight gain as they would for any other patient. Although the integrase strand transfer inhibitors (INSTIs) class of drugs are one of the most popular regimens used for rapid reduction and maintenance in HIV cases, the weight gain resulting from their use is concerning. The use of dolutegravir (DTG) an INSTI is observed to have a weight gain in people living with HIV. Since bictegravir is also an INSTI, it is expected to show a similar weight gain. OBJECTIVE: This retrospective analyses the change in the weight in 22 patients, who showed a trend of increase in weight when on DTG and later when switched to bictegravir therapy showed reduction in the increased weight. METHODS: This is a retrospective analysis from our clinic (Dr. Saple's Clinic) in Mumbai from the duration of March 2018 to March 2021. Excessive weight gain was observed when the patients were on DTG therapy. The therapy was then switched to an equally potent integrase strand inhibitor bictegravir to get the benefit of efficacy of antiretroviral therapy and avoid the weight gain effect seen with DTG. RESULTS: In our case review, we found results contrary to this. After 22 patients were treated on DTG for 9 to 24 months (mean 20.68 months), the baseline weight of 74.04 kg increased significantly to 84.26 kg (P < 0.05). After switching over to bictegravir for a mean period of 8 – 12 months (mean 11.72 months), this weight reduced to mean of 77.08 kg, a drop was clinically observed but was not statistically significant. CONCLUSION: Our finding could be the first instance were weight loss has been reported post switching the patients from DTG therapy to Bictegravir. Considering smaller patient population this outcome may need further confirmed through large group study. Wolters Kluwer - Medknow 2022 2022-06-07 /pmc/articles/PMC9282705/ /pubmed/35846543 http://dx.doi.org/10.4103/ijstd.ijstd_73_21 Text en Copyright: © 2022 Indian Journal of Sexually Transmitted Diseases and AIDS https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Saple, Dattatray
Save, Sushrut
Powar, Ishita
Reduction in the weight, gained due to dolutegravir, following switch to bictegravir
title Reduction in the weight, gained due to dolutegravir, following switch to bictegravir
title_full Reduction in the weight, gained due to dolutegravir, following switch to bictegravir
title_fullStr Reduction in the weight, gained due to dolutegravir, following switch to bictegravir
title_full_unstemmed Reduction in the weight, gained due to dolutegravir, following switch to bictegravir
title_short Reduction in the weight, gained due to dolutegravir, following switch to bictegravir
title_sort reduction in the weight, gained due to dolutegravir, following switch to bictegravir
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282705/
https://www.ncbi.nlm.nih.gov/pubmed/35846543
http://dx.doi.org/10.4103/ijstd.ijstd_73_21
work_keys_str_mv AT sapledattatray reductionintheweightgainedduetodolutegravirfollowingswitchtobictegravir
AT savesushrut reductionintheweightgainedduetodolutegravirfollowingswitchtobictegravir
AT powarishita reductionintheweightgainedduetodolutegravirfollowingswitchtobictegravir